Posted by Michael Wonder on 14 Oct 2023
Intellia Therapeutics receives Priority Medicines (PRIME) designation from the EMA for NTLA-2002, an investigational in vivo CRISPR genome editing treatment for hereditary angioedema
13 October 2023 - Intellia Therapeutics today announced that the EMA has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema.
NTLA-2002 is an in vivo CRISPR based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema.
